~ Boron Maintains Bones, Joints, Neurons and May Reduce Prostate Cancer Risk: References
References
1. Zhang Z-F, Winton MI, Rainey C, et al: Boron is associated with decreased risk of human prostate cancer. FASEB J 15:A1089, 2001.
2. Stacewicz-Sapuntzakis M, Bowen PE, Hussain EA, et al: Chemical composition and potential health effects of prunes: a functional food? Crit Rev Food Sci Nutr 41:251-86, 2001.
3. Gallardo-Williams MT, Maronpot RR, King PE, et al: Effects of boron supplementation on the morphology, PSA levels, and proliferative activity of LNCaP tumors in nude mice. Proc Amer Assoc Cancer Res 43:77, 2002.
4. Murmu N, Ghosh P, Gomes A, et al: Antineoplastic effect of new boron compounds against leukemic cell lines and cells from leukemic patients. J Exp Clin Cancer Res 21:351-6, 2002.
5. Sur P, Ghosh P, Bag SP, et al: On the inhibitory activities of a new boron compound and ultrasound against the mouse ascites tumour. Chemotherapy 45:360-9, 1999.
6. Ghosh P, Sur B, Bag SP, et al: A new boron compound (guanidine biboric acid adduct) as an antitumour agent against Ehrlich ascites carcinoma in mice. Tumour Biol 20:44-51, 1999.
7. Dibas A, Howard J, Anwar S, et al: Borato-1,2-diaminocyclohexane platinum (II), a novel anti-tumor drug. Biochem Biophys Res Commun 270:383- 6, 2000.
8. Hall IH, Elkins A, Powell WJ, et al: Substituted carboranes and polyhedral hydroborate salts as anti-neoplastics. Anticancer Res 18:2617-22, 1998.
9. Hall IH, Elkins AL, Sood A, et al: The cytotoxicity of adenosine 5'-[N,N-di- (gamma-o-carboranyl)propyl] phospho rodiamidate in human Tmolt3 leukemic cells. Anticancer Res 17:151-6, 1997.
10. Webber MM, Waghray A, Bello D: Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1:1089-94, 1995.
11. Nielsen FH: Studies on the relationship between boron and magnesium which possibly affects the formation and maintenance of bones. Magnes Trace Elem 9:61-9, 1990.
12. Nielsen FH, Hunt CD, Mullen LM, et al: Effect of dietary boron on mineral, estrogen, and testosterone metabolism in post-menopausal women. FASEB J 1:394-7, 1987.
13. Gross C, Stamey T, Hancock S, et al: Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 159:2035-9; discussion 2039-40, 1998.
14. Hegsted M, Keenan MJ, Siver F, et al: Effect of boron on vitamin D deficient rats. Biol Trace Elem Res 28:243-55, 1991.
15. Hunt CD, Idso JP: Dietary boron as a physiological regulator of the normal inflammatory response: A review and current research progress. J Trace Elem Exp Med 12:221-233, 1999.
16. Scharla SH, Minne HW, Waibel-Treber S, et al: Bone mass reduction after estrogen deprivation by long-acting gonadotropin-releasing hormone agonists and its relation to pretreatment serum concentrations of 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 70:1055-61, 1990.
17. US Department of Health and Human Services, Surgeon General's report on nutrition and health. Rocklin, CA, Prima Publishing and Communications, 1988.
18. Largo R, Alvarez-Soria MA, Diez-Ortego I, et al: Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 11:290-8, 2003.
19. Fenton JI, Chlebek-Brown KA, Caron JP, et al: Effect of glucosamine on interleukin-1-conditioned articular cartilage. Equine Vet J Suppl:219-23, 2002.
20. Hall IH, Rajendran KG, Chen SY, et al: Anti-inflammatory activity of amine-carboxyboranes in rodents. Arch Pharm (Weinheim) 328:39-44, 1995.
21. Rajendran KG, Chen SY, Sood A, et al: The anti-osteoporotic activity of amine-carboxyboranes in rodents. Biomed Pharmacother 49:131-40, 1995.
22. Hall IH, Starnes CO, McPhail AT, et al: Anti-inflammatory activity of amine cyanoboranes, amine carboxyboranes, and related compounds. J Pharm Sci 69:1025-9, 1980.
23. Newnham RE: Essentiality of boron for healthy bones and joints. Environ Health Perspect 102 Suppl 7:83-5, 1994.
24. Travers RL, Rennie GC, Newnham RE: Boron and arthritis: the result of a double-blind pilot study. J Nutr Med 1:127- 132, 1990.
25. Helliwell TR, Kelly SA, Walsh HP, et al: Elemental analysis of femoral bone from patients with fractured neck of femur or osteoarthrosis. Bone 18:151-7, 1996.
26. Penland JG: Dietary boron, brain function, and cognitive performance. Environ Health Perspect 102 Suppl 7:65-72, 1994.
27. Glorioso S, Todesco S, Mazzi A, et al: Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis. Int J Clin Pharmacol Res 5:39-49, 1985.
28. Gaby AR: Natural treatments for osteo- arthritis. Altern Med Rev 4:330-41, 1999.
29. Konig B: A long-term (two years) clini cal trial with S-adenosylmethionine for the treatment of osteoarthritis. Am J Med 83:89-94, 1987.
30. Ralston NV, Hunt CD: Diadenosine phosphates and S-adenosylmethionine: novel boron binding biomolecules detected by capillary electrophoresis. Biochim Biophys Acta 1527:20-30, 2001.
31. Agdeppa ED, Kepe V, Petri A, et al: In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imag ing probe 2-(1-[6-[(2-[(18)F]fluo- roethyl)(methyl)amino]-2-naphthyl]ethylidene)malono nitrile. Neuroscience 117:723-30, 2003.
32. Blasko I, Grubeck-Loebenstein B: Role of the immune system in the pathogen- esis, prevention and treatment of Alzheimer's disease. Drugs Aging 20:101-13, 2003.
33. Penland JG: The importance of boron nutrition for brain and psychological function. Biol Trace Elem Res 66:299-317, 1998.
34. Benderdour M, Van Bui T, Hess K, et al: Effects of boron derivatives on extracellular matrix formation. J Trace Elem Med Biol 14:168-73, 2000.
35. Nielsen FH: Ultratrace Minerals. In: Modern Nutrition Health Disease. (9th edition), editor M.E. Shils, Baltimore, MD, Lippincott Williams & Wilkins, 1999, pp. 286-288.
36. Olney JW: Role of excitotoxins in developmental neuropathology. APMIS Suppl 40:103-12, 1993.
37. Fail PA, Chapin RE, Price CJ, et al: General, reproductive, developmental, and endocrine toxicity of boronated compounds. Reprod Toxicol 12:1-18, 1998.
38. Murray FJ: A human health risk assess- ment of boron (boric acid and borax) in drinking water. Regul Toxicol Pharmacol 22:221-30, 1995.
39. Linden CH, Hall AH, Kulig KW, et al: Acute ingestions of boric acid. J Toxicol Clin Toxicol 24:269-79, 1986.
40. Pinto J, Huang YP, McConnell RJ, et al: Increased urinary riboflavin excre tion resulting from boric acid ingestion. J Lab Clin Med 92:126-34, 1978.
41. Gordon AS, Prichard JS, Freedman MH: Seizure disorders and anemia associated with chronic borax intoxica- tion. Can Med Assoc J 108:719-21, 1973.
42. Hubbard SA: Comparative toxicology of borates. Biol Trace Elem Res 66:343-57, 1998.
43. Pan XQ, Wang H, Shukla S, et al: Boron-containing folate receptor-targeted liposomes as potential delivery agents for neutron capture therapy. Bioconjug Chem 13:435-42, 2002.
44. Shukla S, Wu G, Chatterjee M, et al: Synthesis and Biological Evaluation of Folate Receptor-Targeted Boronated PAMAM Dendrimers as Potential Agents for Neutron Capture Therapy. Bioconjug Chem 14:158-67, 2003.
45. Pan XQ, Wang H, Lee RJ: Boron delivery to a murine lung carcinoma using folate receptor-targeted liposomes. Anticancer Res 22:1629-33, 2002.
46. Valliant JF, Schaffer P, Stephenson KA, et al: Synthesis of boroxifen, a nido- carborane analogue of tamoxifen. J Org Chem 67:383-7, 2002.
47. Vicente MG: Porphyrin-based Sensitizers in the Detection and Treatment of Cancer: Recent Progress. Curr Med Chem Anti-Canc Agents 1:175-94, 2001.
48. Hill JS, Kahl SB, Stylli SS, et al: Selective tumor kill of cerebral glioma by photodynamic therapy using a boronated porphyrin photosensitizer. Proc Natl Acad Sci U S A 92:12126-30, 1995.
49. Yamada Y, Toda K, Kahl SB, et al: Enhanced therapeutic effect on murine melanoma and angiosarcoma cells by boron neutron capture therapy using a boronated metalloporphyrin. Kobe J Med Sci 40:25-37, 1994.
50. Shahbazi-Gahrouei D, Williams M, Rizvi S, et al: In vivo studies of Gd- DTPA-mono-clonal antibody and gd- porphyrins: potential magnetic reso nance imaging contrast agents for melanoma. J Magn Reson Imaging 14:169-74, 2001.
51. Kreimann EL, Miura M, Itoiz ME, et al: Biodistribution of a carborane-containing porphyrin as a targeting agent for Boron Neutron Capture Therapy of oral cancer in the hamster cheek pouch. Arch Oral Biol 48:223-32, 2003.
52. Miura M, Joel DD, Smilowitz HM, et al: Biodistribution of copper carbo ranyltetraphenylporphyrins in rodents bearing an isogeneic or human neo-plasm. J Neurooncol 52:111-7, 2001.
53. Miura M, Morris GM, Micca PL, et al: Boron Neutron Capture Therapy of a Murine Mammary Carcinoma using a LipophilicCarboranyltetraphenylporphyrin. Radiat Res 155:603-610, 2001.
54. Callahan DE, Forte TM, Afzal SM, et al: Boronated protoporphyrin (BOPP): local-ization in lysosomes of the human glioma cell line SF-767 with uptake modulated by lipoprotein levels. Int J Radiat Oncol Biol Phys 45:761-71, 1999.
55. Nichols TL, Kabalka GW, Miller LF, et al: Improved treatment planning for boron neutron capture therapy for glioblastoma multiforme using fluorine-18 labeled boronophenylalanine and positron emission tomography. Med Phys 29:2351-8, 2002.
56. Kabalka GW, Nichols TL, Smith GT, et al: The use of positron emission tomography to develop boron neutron capture therapy treatment plans for metastatic malignant melanoma. J Neurooncol 62:187-95, 2003.
57. Hawthorne MF: Condensed version of the 79th faculty research lecture, Department of Chemistry and Biochemistry at UCLA, 1995
58. Diaz AZ, Coderre JA, Chanana AD, et al: Boron neutron capture therapy for malignant gliomas. Ann Med 32:81-5, 2000.
59. Hawthorne MF, Lee MW: A critical assessment of boron target compounds for boron neutron capture therapy. J Neurooncol 62:33-45, 2003.
60. Hunt CD, Nielsen FH: Dietary boron affects bone calcification in magnesium and chole-calciferol deficient chicks. In: Trace elements in human and animal nutrition. (5th edition), editor W. Mertz, New York, Academic Press, 1986, pp. 275-277.
61. Hunt CD, Nielsen FH: Interaction between boron and cholecalciferol in the chick. In: Trace elements in human and animal nutrition. (4th edition), editor E.J. Underwood, New York, Academic Press, 1977, pp. 597-600.
62. Hunt CD, Herbel JL, Idso JP: Dietary boron modifies the effects of vitamin D3 nutrition on indices of energy substrate utilization and mineral metabolism in the chick. J Bone Miner Res 9:171-82,1994.
63. Bai Y, Hunt CD: Dietary boron enhances efficacy of cholecalciferol in broiler chicks. J Trace Elem Exp Med 9:117-132, 1996.
64. Hunt CD: Biochemical effects of physiological amounts of dietary boron. J Trace Elem Exp Med 9:185-213, 1996.
65. Nielsen FH, Penland JG: Boron supplementation of perimenopausal women affects boron metabolism and indices associated with macromineral metabolism, hormonal status and immune function. J Trace Elem Exp Med 12:251-261, 1999.
66. Hunt CD: The biochemical effects of physiologic amounts of dietary boron in animal nutrition models. Environ Health Perspect 102 Suppl 7:35-43, 1994.
67. Nielsen FH: Boron in human and animal nutrition. Plant and Soil 193:199- 208, 1997.
1. Zhang Z-F, Winton MI, Rainey C, et al: Boron is associated with decreased risk of human prostate cancer. FASEB J 15:A1089, 2001.
2. Stacewicz-Sapuntzakis M, Bowen PE, Hussain EA, et al: Chemical composition and potential health effects of prunes: a functional food? Crit Rev Food Sci Nutr 41:251-86, 2001.
3. Gallardo-Williams MT, Maronpot RR, King PE, et al: Effects of boron supplementation on the morphology, PSA levels, and proliferative activity of LNCaP tumors in nude mice. Proc Amer Assoc Cancer Res 43:77, 2002.
4. Murmu N, Ghosh P, Gomes A, et al: Antineoplastic effect of new boron compounds against leukemic cell lines and cells from leukemic patients. J Exp Clin Cancer Res 21:351-6, 2002.
5. Sur P, Ghosh P, Bag SP, et al: On the inhibitory activities of a new boron compound and ultrasound against the mouse ascites tumour. Chemotherapy 45:360-9, 1999.
6. Ghosh P, Sur B, Bag SP, et al: A new boron compound (guanidine biboric acid adduct) as an antitumour agent against Ehrlich ascites carcinoma in mice. Tumour Biol 20:44-51, 1999.
7. Dibas A, Howard J, Anwar S, et al: Borato-1,2-diaminocyclohexane platinum (II), a novel anti-tumor drug. Biochem Biophys Res Commun 270:383- 6, 2000.
8. Hall IH, Elkins A, Powell WJ, et al: Substituted carboranes and polyhedral hydroborate salts as anti-neoplastics. Anticancer Res 18:2617-22, 1998.
9. Hall IH, Elkins AL, Sood A, et al: The cytotoxicity of adenosine 5'-[N,N-di- (gamma-o-carboranyl)propyl] phospho rodiamidate in human Tmolt3 leukemic cells. Anticancer Res 17:151-6, 1997.
10. Webber MM, Waghray A, Bello D: Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1:1089-94, 1995.
11. Nielsen FH: Studies on the relationship between boron and magnesium which possibly affects the formation and maintenance of bones. Magnes Trace Elem 9:61-9, 1990.
12. Nielsen FH, Hunt CD, Mullen LM, et al: Effect of dietary boron on mineral, estrogen, and testosterone metabolism in post-menopausal women. FASEB J 1:394-7, 1987.
13. Gross C, Stamey T, Hancock S, et al: Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 159:2035-9; discussion 2039-40, 1998.
14. Hegsted M, Keenan MJ, Siver F, et al: Effect of boron on vitamin D deficient rats. Biol Trace Elem Res 28:243-55, 1991.
15. Hunt CD, Idso JP: Dietary boron as a physiological regulator of the normal inflammatory response: A review and current research progress. J Trace Elem Exp Med 12:221-233, 1999.
16. Scharla SH, Minne HW, Waibel-Treber S, et al: Bone mass reduction after estrogen deprivation by long-acting gonadotropin-releasing hormone agonists and its relation to pretreatment serum concentrations of 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 70:1055-61, 1990.
17. US Department of Health and Human Services, Surgeon General's report on nutrition and health. Rocklin, CA, Prima Publishing and Communications, 1988.
18. Largo R, Alvarez-Soria MA, Diez-Ortego I, et al: Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 11:290-8, 2003.
19. Fenton JI, Chlebek-Brown KA, Caron JP, et al: Effect of glucosamine on interleukin-1-conditioned articular cartilage. Equine Vet J Suppl:219-23, 2002.
20. Hall IH, Rajendran KG, Chen SY, et al: Anti-inflammatory activity of amine-carboxyboranes in rodents. Arch Pharm (Weinheim) 328:39-44, 1995.
21. Rajendran KG, Chen SY, Sood A, et al: The anti-osteoporotic activity of amine-carboxyboranes in rodents. Biomed Pharmacother 49:131-40, 1995.
22. Hall IH, Starnes CO, McPhail AT, et al: Anti-inflammatory activity of amine cyanoboranes, amine carboxyboranes, and related compounds. J Pharm Sci 69:1025-9, 1980.
23. Newnham RE: Essentiality of boron for healthy bones and joints. Environ Health Perspect 102 Suppl 7:83-5, 1994.
24. Travers RL, Rennie GC, Newnham RE: Boron and arthritis: the result of a double-blind pilot study. J Nutr Med 1:127- 132, 1990.
25. Helliwell TR, Kelly SA, Walsh HP, et al: Elemental analysis of femoral bone from patients with fractured neck of femur or osteoarthrosis. Bone 18:151-7, 1996.
26. Penland JG: Dietary boron, brain function, and cognitive performance. Environ Health Perspect 102 Suppl 7:65-72, 1994.
27. Glorioso S, Todesco S, Mazzi A, et al: Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis. Int J Clin Pharmacol Res 5:39-49, 1985.
28. Gaby AR: Natural treatments for osteo- arthritis. Altern Med Rev 4:330-41, 1999.
29. Konig B: A long-term (two years) clini cal trial with S-adenosylmethionine for the treatment of osteoarthritis. Am J Med 83:89-94, 1987.
30. Ralston NV, Hunt CD: Diadenosine phosphates and S-adenosylmethionine: novel boron binding biomolecules detected by capillary electrophoresis. Biochim Biophys Acta 1527:20-30, 2001.
31. Agdeppa ED, Kepe V, Petri A, et al: In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imag ing probe 2-(1-[6-[(2-[(18)F]fluo- roethyl)(methyl)amino]-2-naphthyl]ethylidene)malono nitrile. Neuroscience 117:723-30, 2003.
32. Blasko I, Grubeck-Loebenstein B: Role of the immune system in the pathogen- esis, prevention and treatment of Alzheimer's disease. Drugs Aging 20:101-13, 2003.
33. Penland JG: The importance of boron nutrition for brain and psychological function. Biol Trace Elem Res 66:299-317, 1998.
34. Benderdour M, Van Bui T, Hess K, et al: Effects of boron derivatives on extracellular matrix formation. J Trace Elem Med Biol 14:168-73, 2000.
35. Nielsen FH: Ultratrace Minerals. In: Modern Nutrition Health Disease. (9th edition), editor M.E. Shils, Baltimore, MD, Lippincott Williams & Wilkins, 1999, pp. 286-288.
36. Olney JW: Role of excitotoxins in developmental neuropathology. APMIS Suppl 40:103-12, 1993.
37. Fail PA, Chapin RE, Price CJ, et al: General, reproductive, developmental, and endocrine toxicity of boronated compounds. Reprod Toxicol 12:1-18, 1998.
38. Murray FJ: A human health risk assess- ment of boron (boric acid and borax) in drinking water. Regul Toxicol Pharmacol 22:221-30, 1995.
39. Linden CH, Hall AH, Kulig KW, et al: Acute ingestions of boric acid. J Toxicol Clin Toxicol 24:269-79, 1986.
40. Pinto J, Huang YP, McConnell RJ, et al: Increased urinary riboflavin excre tion resulting from boric acid ingestion. J Lab Clin Med 92:126-34, 1978.
41. Gordon AS, Prichard JS, Freedman MH: Seizure disorders and anemia associated with chronic borax intoxica- tion. Can Med Assoc J 108:719-21, 1973.
42. Hubbard SA: Comparative toxicology of borates. Biol Trace Elem Res 66:343-57, 1998.
43. Pan XQ, Wang H, Shukla S, et al: Boron-containing folate receptor-targeted liposomes as potential delivery agents for neutron capture therapy. Bioconjug Chem 13:435-42, 2002.
44. Shukla S, Wu G, Chatterjee M, et al: Synthesis and Biological Evaluation of Folate Receptor-Targeted Boronated PAMAM Dendrimers as Potential Agents for Neutron Capture Therapy. Bioconjug Chem 14:158-67, 2003.
45. Pan XQ, Wang H, Lee RJ: Boron delivery to a murine lung carcinoma using folate receptor-targeted liposomes. Anticancer Res 22:1629-33, 2002.
46. Valliant JF, Schaffer P, Stephenson KA, et al: Synthesis of boroxifen, a nido- carborane analogue of tamoxifen. J Org Chem 67:383-7, 2002.
47. Vicente MG: Porphyrin-based Sensitizers in the Detection and Treatment of Cancer: Recent Progress. Curr Med Chem Anti-Canc Agents 1:175-94, 2001.
48. Hill JS, Kahl SB, Stylli SS, et al: Selective tumor kill of cerebral glioma by photodynamic therapy using a boronated porphyrin photosensitizer. Proc Natl Acad Sci U S A 92:12126-30, 1995.
49. Yamada Y, Toda K, Kahl SB, et al: Enhanced therapeutic effect on murine melanoma and angiosarcoma cells by boron neutron capture therapy using a boronated metalloporphyrin. Kobe J Med Sci 40:25-37, 1994.
50. Shahbazi-Gahrouei D, Williams M, Rizvi S, et al: In vivo studies of Gd- DTPA-mono-clonal antibody and gd- porphyrins: potential magnetic reso nance imaging contrast agents for melanoma. J Magn Reson Imaging 14:169-74, 2001.
51. Kreimann EL, Miura M, Itoiz ME, et al: Biodistribution of a carborane-containing porphyrin as a targeting agent for Boron Neutron Capture Therapy of oral cancer in the hamster cheek pouch. Arch Oral Biol 48:223-32, 2003.
52. Miura M, Joel DD, Smilowitz HM, et al: Biodistribution of copper carbo ranyltetraphenylporphyrins in rodents bearing an isogeneic or human neo-plasm. J Neurooncol 52:111-7, 2001.
53. Miura M, Morris GM, Micca PL, et al: Boron Neutron Capture Therapy of a Murine Mammary Carcinoma using a LipophilicCarboranyltetraphenylporphyrin. Radiat Res 155:603-610, 2001.
54. Callahan DE, Forte TM, Afzal SM, et al: Boronated protoporphyrin (BOPP): local-ization in lysosomes of the human glioma cell line SF-767 with uptake modulated by lipoprotein levels. Int J Radiat Oncol Biol Phys 45:761-71, 1999.
55. Nichols TL, Kabalka GW, Miller LF, et al: Improved treatment planning for boron neutron capture therapy for glioblastoma multiforme using fluorine-18 labeled boronophenylalanine and positron emission tomography. Med Phys 29:2351-8, 2002.
56. Kabalka GW, Nichols TL, Smith GT, et al: The use of positron emission tomography to develop boron neutron capture therapy treatment plans for metastatic malignant melanoma. J Neurooncol 62:187-95, 2003.
57. Hawthorne MF: Condensed version of the 79th faculty research lecture, Department of Chemistry and Biochemistry at UCLA, 1995
58. Diaz AZ, Coderre JA, Chanana AD, et al: Boron neutron capture therapy for malignant gliomas. Ann Med 32:81-5, 2000.
59. Hawthorne MF, Lee MW: A critical assessment of boron target compounds for boron neutron capture therapy. J Neurooncol 62:33-45, 2003.
60. Hunt CD, Nielsen FH: Dietary boron affects bone calcification in magnesium and chole-calciferol deficient chicks. In: Trace elements in human and animal nutrition. (5th edition), editor W. Mertz, New York, Academic Press, 1986, pp. 275-277.
61. Hunt CD, Nielsen FH: Interaction between boron and cholecalciferol in the chick. In: Trace elements in human and animal nutrition. (4th edition), editor E.J. Underwood, New York, Academic Press, 1977, pp. 597-600.
62. Hunt CD, Herbel JL, Idso JP: Dietary boron modifies the effects of vitamin D3 nutrition on indices of energy substrate utilization and mineral metabolism in the chick. J Bone Miner Res 9:171-82,1994.
63. Bai Y, Hunt CD: Dietary boron enhances efficacy of cholecalciferol in broiler chicks. J Trace Elem Exp Med 9:117-132, 1996.
64. Hunt CD: Biochemical effects of physiological amounts of dietary boron. J Trace Elem Exp Med 9:185-213, 1996.
65. Nielsen FH, Penland JG: Boron supplementation of perimenopausal women affects boron metabolism and indices associated with macromineral metabolism, hormonal status and immune function. J Trace Elem Exp Med 12:251-261, 1999.
66. Hunt CD: The biochemical effects of physiologic amounts of dietary boron in animal nutrition models. Environ Health Perspect 102 Suppl 7:35-43, 1994.
67. Nielsen FH: Boron in human and animal nutrition. Plant and Soil 193:199- 208, 1997.
Free Shipping in the Continental U.S. on Orders over $50
The statements made here have not been evaluated by the FDA. The foregoing statements are based upon sound and reliable studies, and are meant for informational purposes. Consult with your medical practitioner to determine the underlying cause of your symptoms. Please always check your purchase for possible allergins and correct dosage on the bottle before use.
While we work to ensure that product information is correct, on occasion manufacturers may alter their ingredient lists. Actual product packaging and materials may contain more and/or different information than that shown on our Web site. We recommend that you do not solely rely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. For additional information about a product, please contact the manufacturer. Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional. You should not use this information as self-diagnosis or for treating a health problem or disease. Contact your health-care provider immediately if you suspect that you have a medical problem. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or health condition. Life Ex Online assumes no liability for inaccuracies or misstatements about products.
- Life Extension - Life Extension Vitamins
- Metabolism-Garcinia HCA Life Extension
- Glucose Management
- Longevity & Wellness
- Antioxidants
- Body Care
- Bones
- Brain
- Chinese / Mushrooms
- Digestion
- Energy / Sports
- Health Concerns
- Heart / Circulation
- Hormone / Prostate
- Immune
- Inflammatory Factors
- Intimacy
- Liver / Urinary
- Phyto Extracts
- Powdered Supplements
- Seasonal / Respiratory
- Vitamins / Multivitamins / Aminos / Minerals
- Life Extension CoQ10
